1. Uno H, Zimbric ML, Albert DM, Stjernschantz J. Effect of latano-prost on hair growth in the bald scalp of the stump-tailed mac-acque: a pilot study. Acta Derm Venereol. 2002; 82:7–12.
Article
2. Sugimoto M, Sugimoto M, Uji Y. Quantitative analysis of eyelash lengthening following topical latanoprost therapy. Can J Ophthalmol. 2002; 37:342–5.
Article
3. Hart J, Shafranov G. Hypertrichosis of vellus hairs ofthe malar re-gion after unilateral treatment with bimatoprost. Am J Ophthalmol. 2004; 137:756–7.
4. Woodward DF, Wang JW, Poloso NJ. Recent progress in prosta-glandin F2alpha ethanolamide (prostamide F2alpha) research and therapeutics. Pharmacol Rev. 2013; 65:1135–47.
5. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regu-lator of multiple epidermal functions. Eur J Dermatol. 2000; 10:505–10.
6. Van den Eynde M, Baurain JF, Mazzeo F, Machiels JP. Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clin Belg. 2011; 66:10–7.
Article
7. Schneider MR, Wolf E. The epidermal growth factor receptor li-gands at a glance. J Cell Physiol. 2009; 218:460–6.
Article
8. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004; 59:21–6.
Article
9. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012; 12:553–63.
Article
10. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011; 364:947–55.
Article
11. Alexandrescu DT, Kauffman CL, Dasanu CA. The cutaneous epi-dermal growth factor network: Can it be translated clinically to stimulate hair growth. Dermatol Online J. 2009; 15:1.
Article
12. Balagula Y, Garbe C, Myskowski PL, et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol. 2011; 50:129–46.
Article
13. Mittmann N, Seung SJ. Rash rates with egfr inhibitors: meta-analysis. Curr Oncol. 2011; 18:54–63.
Article
14. Methvin AB, Gausas RE. Newly recognized ocular side effects of erlotinib. Ophthal Plast Reconstr Surg. 2007; 23:63–5.
Article
15. Hansen LA, Alexander N, Hogan ME, et al. Genetically null mice reveal a central role for epidermal growth factor receptor in the dif-ferentiation of the hair follicle and normal hair development. Am J Pathol. 1997; 150:1959–75.
16. Dueland S, Sauer T, Lund-Johansen F, et al. Epidermal growth fac-tor receptor inhibition induces trichomegaly. Acta Oncol. 2003; 42:345–6.
Article
17. Vergou T, Stratigos AJ, Karapanagiotou EM, et al. Facial hyper-trichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol. 2010; 63:56–8.
Article
18. Cohen PR, Escudier SM, Kurzrock R. Cetuximab-associated elon-gation of the eyelashes: case report and review of eyelash tricho-megaly secondary to epidermal growth factor receptor inhibitors. Am J Clin Dermatol. 2011; 12:63–7.
19. Fabbrocini G, Panariello L, Cacciapuoti S, et al. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases. Dermatitis. 2012; 23:237–8.
20. Paul LJ, Cohen PR, Kurzrock R. Eyelash trichomegaly: review of congenital, acquired, and drug-associated etiologies for elongation of the eyelashes. Int J Dermatol. 2012; 51:631–46.
Article
21. Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eye-lashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol. 2008; 26:3460–2.
Article
22. Zhang G, Basti S, Jampol LM. Acquired trichomegaly and sympto-matic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature. Cornea. 2007; 26:858–60.
23. Li T, Perez-Soler R. Skin toxi cities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009; 4:107–19.
24. Alexandrescu DT, Kauffman CL, Dasanu CA. Persistent hair growth during treatment with the EGFR inhibitor erlotinib. Dermatol Online J. 2009; 15:4.
Article
25. Papadopoulos R, Chasapi V, Bachariou A. Trichomegaly induced by erlotinib. Orbit. 2008; 27:329–30.
Article
26. Morse L, Calarese P. EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs. 2006; 22:152–62.
Article
27. Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor re-ceptor inhibitors. Br J Dermatol. 2009; 161:515–21.
Article
28. Cohen JL. Enhancing the growth of natural eyelashes: the mecha-nism ofbimatoprost-induced eyelash growth. Dermatol Surg. 2010; 36:1361–71.
29. Nakamura Y, Sotozono C, Kinoshita S. The epidermal growth fac-tor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res. 2001; 72:511–7.
Article
30. Wilson SE, He YG, Weng J, et al. Effect of epidermal growth fac-tor, hepatocyte growth factor, and keratinocyte growth factor, on proliferation, motility and differentiation of human corneal epi-thelial cells. Exp Eye Res. 1994; 59:665–78.
Article
31. Saint-Jean A, Sainz de la Maza M, Morral M, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor re-ceptor: report of 5 cases. Ophthalmology. 2012; 119:1798–802.
Article
32. Tullo AB, Esmaeli B, Murray PI, et al. Ocular findings in patients with solid tumours treated with the epidermal growth factor re-ceptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Phase I and II clinical trials. Eye (Lond). 2005; 19:729–38.
Article